The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial

Inclusion Criteria: * Obtain signed informed consent from the patient or their legal representative, with adherence to the study protocol and follow-up procedures; * Aged \>=18 and \<=80 years, regardless of gender; * No contraindications to surgery, with an ECOG performance status of 0-1; * Confirmed peritoneal metastasis by imaging or intraoperative detection, with rapid intraoperative histopathology indicating metastatic adenocarcinoma; * No prior anti-tumor therapy before treatment, including systemic chemotherapy, interventional chemotherapy, high-intensity focused ultrasound (HIFU), radiotherapy, immunotherapy, molecular targeted therapy, or traditional Chinese medicine anti-tumor treatments; * No severe hematological, cardiac, pulmonary dysfunction, or autoimmune deficiency (based on respective diagnostic criteria); * Hematological criteria: White blood cells (WBC) \>=3.0 × 10⁹/L; Absolute neutrophil count (ANC) \>=1.5 × 10⁹/L; Platelets (PLT) \>=100 × 10⁹/L; Hemoglobin (Hgb) \>=90 g/L. * Blood biochemistry criteria: AST (SGOT) and ALT (SGPT) \<=2.5 × upper limit of normal (ULN); Total bilirubin (TBIL) \<=2 × ULN; Serum creatinine (CRE) \<=1.5 × ULN. * Coagulation function: Prothrombin time (PT) and international normalized ratio (INR) \<=1.5 × ULN; * Compliance with study visit schedules and other protocol requirements. Exclusion Criteria: * Presence of distant metastases to other organs (e.g., liver, bone, lung) with definitive evidence, except for ovarian metastases; * History of other systemic malignancies within the past five years; * Use of any non-anti-tumor investigational drugs within 4 weeks prior to treatment; * Accompanied by massive ascites (extending from pelvic to upper abdominal cavity); * History of upper gastrointestinal bleeding requiring repeated blood transfusions within the past three months; * Pregnancy, autoimmune diseases, severe hyperthyroidism/hypothyroidism, central nervous system disorders, psychiatric illnesses, unstable angina, congestive heart failure, severe arrhythmias, or other uncontrolled serious medical conditions; * History of hypersensitivity to the study drugs or medications with similar chemical structures; * Patients requiring long-term warfarin anticoagulation therapy; * Poor compliance, inability or unwillingness to provide signed informed consent; * Patients likely to be lost to follow-up for ≥14 days during the treatment period.